 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on May 20, 2016 |
| Title |
Transcriptome data of multiple sclerosis patients receiving fingolimod therapy [HTA-2_0, CD19+ cells, gene level] |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
We analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS).
Affymetrix Human Transcriptome Arrays (HTA) 2.0 were used to obtain gene expression profiles of immune cell populations from 10 RRMS patients within the first 3 months of fingolimod treatment.
This GEO entry provides the Affymetrix HTA 2.0 microarray data of peripheral blood CD19+ cells, preprocessed according to the gene level workflow.
|
| |
|
| Overall design |
EDTA blood samples were taken from all patients immediately before first and second fingolimod administration as well as after 3 months of therapy.
Total RNA of CD19+ cells positively selected from each blood sample was extracted, labeled and hybridized to high-density Affymetrix HTA 2.0 microarrays to quantify the transcript levels.
|
| |
|
| Contributor(s) |
Hecker M, Koczan D, Zettl UK |
| Citation(s) |
29314605, 30040082 |
| |
| Submission date |
May 18, 2016 |
| Last update date |
Oct 29, 2018 |
| Contact name |
Michael Hecker |
| E-mail(s) |
michael.hecker@rocketmail.com
|
| Organization name |
University of Rostock
|
| Department |
Department of Neurology
|
| Lab |
Division of Neuroimmunology
|
| Street address |
Gehlsheimer Str. 20
|
| City |
Rostock |
| ZIP/Postal code |
18147 |
| Country |
Germany |
| |
|
| Platforms (1) |
| GPL17586 |
[HTA-2_0] Affymetrix Human Transcriptome Array 2.0 [transcript (gene) version] |
|
| Samples (30)
|
| GSM2157869 |
Patient 1, CD19+ cells, before first dose of fingolimod [gene-level] |
| GSM2157870 |
Patient 1, CD19+ cells, before second dose of fingolimod [gene-level] |
| GSM2157871 |
Patient 1, CD19+ cells, after 3 months of fingolimod treatment [gene-level] |
| GSM2157872 |
Patient 2, CD19+ cells, before first dose of fingolimod [gene-level] |
| GSM2157873 |
Patient 2, CD19+ cells, before second dose of fingolimod [gene-level] |
| GSM2157874 |
Patient 2, CD19+ cells, after 3 months of fingolimod treatment [gene-level] |
| GSM2157875 |
Patient 3, CD19+ cells, before first dose of fingolimod [gene-level] |
| GSM2157876 |
Patient 3, CD19+ cells, before second dose of fingolimod [gene-level] |
| GSM2157877 |
Patient 3, CD19+ cells, after 3 months of fingolimod treatment [gene-level] |
| GSM2157878 |
Patient 4, CD19+ cells, before first dose of fingolimod [gene-level] |
| GSM2157879 |
Patient 4, CD19+ cells, before second dose of fingolimod [gene-level] |
| GSM2157880 |
Patient 4, CD19+ cells, after 3 months of fingolimod treatment [gene-level] |
| GSM2157881 |
Patient 5, CD19+ cells, before first dose of fingolimod [gene-level] |
| GSM2157882 |
Patient 5, CD19+ cells, before second dose of fingolimod [gene-level] |
| GSM2157883 |
Patient 5, CD19+ cells, after 3 months of fingolimod treatment [gene-level] |
| GSM2157884 |
Patient 6, CD19+ cells, before first dose of fingolimod [gene-level] |
| GSM2157885 |
Patient 6, CD19+ cells, before second dose of fingolimod [gene-level] |
| GSM2157886 |
Patient 6, CD19+ cells, after 3 months of fingolimod treatment [gene-level] |
| GSM2157887 |
Patient 7, CD19+ cells, before first dose of fingolimod [gene-level] |
| GSM2157888 |
Patient 7, CD19+ cells, before second dose of fingolimod [gene-level] |
| GSM2157889 |
Patient 7, CD19+ cells, after 3 months of fingolimod treatment [gene-level] |
| GSM2157890 |
Patient 8, CD19+ cells, before first dose of fingolimod [gene-level] |
| GSM2157891 |
Patient 8, CD19+ cells, before second dose of fingolimod [gene-level] |
| GSM2157892 |
Patient 8, CD19+ cells, after 3 months of fingolimod treatment [gene-level] |
| GSM2157893 |
Patient 9, CD19+ cells, before first dose of fingolimod [gene-level] |
| GSM2157894 |
Patient 9, CD19+ cells, before second dose of fingolimod [gene-level] |
| GSM2157895 |
Patient 9, CD19+ cells, after 3 months of fingolimod treatment [gene-level] |
| GSM2157896 |
Patient 10, CD19+ cells, before first dose of fingolimod [gene-level] |
| GSM2157897 |
Patient 10, CD19+ cells, before second dose of fingolimod [gene-level] |
| GSM2157898 |
Patient 10, CD19+ cells, after 3 months of fingolimod treatment [gene-level] |
|
| This SubSeries is part of SuperSeries: |
| GSE73174 |
Transcriptome data of multiple sclerosis patients receiving fingolimod therapy |
|
| Relations |
| BioProject |
PRJNA322150 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE81604_RAW.tar |
651.7 Mb |
(http)(custom) |
TAR (of CEL, CHP) |
| Processed data included within Sample table |
| Processed data provided as supplementary file |
|
|
|
|
 |
Less...
More...